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Background: The Evaluate Patient OutComes (EPOC) study assessed physician- and patient-reported outcomes in
individuals with relapsing multiple sclerosis who switched directly from injectable disease-modifying therapy (iDMT;
glatiramer acetate, intramuscular or subcutaneous interferon beta-1a, or interferon beta-1b) to once-daily, oral
fingolimod. Post hoc analyses evaluated the impact of a switch to fingolimod versus staying on each of the four
individual iDMTs.
Methods: Overall, 1053 patients were randomized 3:1 to switch to fingolimod or remain on iDMT. The primary
endpoint was the change in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction score.
Secondary endpoints included changes in scores for TSQM Effectiveness, Side Effects and Convenience subscales,
Beck Depression Inventory-II (BDI-II), Fatigue Severity Scale (FSS), Patient-Reported Outcome Indices for Multiple
Sclerosis (PRIMUS) Activities, 36-item Short-Form Health Survey (SF-36) Mental Component Summary (MCS) and
Physical Component Summary (PCS) and mean investigator-reported Clinical Global Impressions of Improvement
(CGI-I). All outcomes were evaluated after 6 months of treatment.
Results: Changes in TSQM Global Satisfaction scores were superior after a switch to fingolimod when compared
with scores in patients remaining on any of the iDMTs (all p <0.001). Likewise, all TSQM subscale scores improved
following a switch to fingolimod (all p <0.001), except when compared with glatiramer acetate for the TSQM Side
Effects subscale (p = 0.111). FSS scores were found to be superior for fingolimod versus remaining on subcutaneous
interferon beta-1a and interferon beta-1b, BDI-II scores were significantly improved for fingolimod except for the
comparison with intramuscular interferon beta-1a, and SF-36 scores were superior with fingolimod compared with
remaining on interferon beta-1b (MCS and PCS; p = 0.030 and p = 0.022, respectively) and subcutaneous interferon
beta-1a (PCS only; p = 0.024). Mean CGI-I scores were superior with fingolimod when compared with continuing
treatment with any of the iDMTs (all p <0.001).
Conclusions: After 6 months, a switch to fingolimod showed superiority compared with remaining on each iDMT
for a range of patient- and physician-reported outcomes, including global satisfaction with treatment.
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Fingolimod is a disease-modifying therapy (DMT) that is
administered as an oral tablet [1]; it is the first once-daily,
oral immunotherapy for the treatment of relapsing mul-
tiple sclerosis (MS) approved by the US Food and Drug
Administration. Relapsing MS is a disease characterized
by phases of neurological deficits followed by stable pe-
riods, eventually resulting in accumulated neurological
deterioration that increases disability [2,3] and reduces
quality of life (QOL) [4]. Fingolimod exerts its therapeutic
effects via modulation of sphingosine 1-phosphate re-
ceptors on T-lymphocytes, which results in the selective
and reversible retention of naïve and central memory
T-lymphocytes within lymph nodes, preventing their
circulation to other tissues, including the central ner-
vous system.
Prior to the approval of fingolimod, treatment of MS
commonly used injectable DMTs (iDMTs) such as beta in-
terferons (IFNs) or glatiramer acetate (GA). However, pa-
tients face various issues with use of self-administered
injections of these therapies, such as anxiety over the use
of needles, tolerability problems and injection-site side ef-
fects relating to long-term use [5,6]. In addition, iDMTs
have shown limited efficacy in some patients [7,8].
The phase 3 TRANSFORMS and FREEDOMS trials
have demonstrated fingolimod to be superior to placebo
and intramuscular (IM) IFN beta-1a in reducing relapse
rate and in terms of magnetic resonance imaging (MRI)
measures [9,10]. Evidence that fingolimod significantly im-
proves health-related QOL and patient-reported outcomes
(PROs) in comparison with placebo has also been reported
[11]. In order to determine the impact of fingolimod ver-
sus active comparators on health-related QOL, the open-
label Evaluate Patient OutComes (EPOC; NCT01216072)
study was conducted. EPOC was the first trial comparing
a switch to fingolimod versus remaining on any of four
iDMTs (either GA or one of three IFN betas) on a range
of physician-related outcomes and PROs [12]. EPOC
showed that, after switching to fingolimod therapy for
6 months, patients had significant improvements in most
self-reported outcomes when compared with those who
continued to receive an iDMT, including satisfaction
with treatment, fatigue severity, depression severity,
physical function and mental health [13]. In addition, by
including a broader patient population than was included
in the registration trials, and by allowing treatments to beswitched with no washout period, the EPOC study has
provided information regarding a treatment switch in a
real-world scenario.
These post hoc analyses examined the effects of a ther-
apy switch to fingolimod on the different outcome mea-
sures assessed in the EPOC trial and compared them
with remaining on each of the four individual iDMTs. The
rationale for conducting the current study was that the
primary analysis was restricted to comparison of fingoli-
mod with iDMTs as a single group, whereas the post hoc
analyses presented here focused on the comparison of a
switch to fingolimod from each individual iDMT versus
remaining on each individual iDMT. This study therefore
aimed to determine whether there were specific iDMTs
for which patients would benefit from a switch of therapy.
Methods
Study design
EPOC was a 6-month, randomized, open-label, multicenter,
phase 4 study conducted in the USA and Canada. Patients
were randomized 3:1 to switch to fingolimod (FTY720;
Gilenya®, Novartis Pharma AG, Basel, Switzerland) 0.5 mg
or remain on/switch to an iDMT for 6 months with no
intervening washout period. The primary analysis evaluated
two groups, namely fingolimod versus any iDMT. Patients
randomized to the iDMT group either remained on the
same therapy or, following consultation with a phys-
ician, were switched immediately to another approved
iDMT. The four iDMTs were subcutaneous (SC) IFN
beta-1b (Extavia®, Novartis Pharma AG, Basel, Switzerland,
or Betaseron®, Bayer AG, Leverkusen, Germany) 0.25 mg
every other day, IM IFN beta-1a (Avonex®, Biogen Idec,
Cambridge, MA, USA) 30 μg once weekly, SC IFN beta-1a
(Rebif®, Merck Serono, Darmstadt, Germany, and Pfizer
Inc., New York City, NY, USA) 22 or 44 μg three times
weekly, or SC GA (Copaxone®, Teva Pharmaceutical Indus-
tries Ltd, Petah Tikva, Israel) 20 mg once daily. The proto-
col and informed consent form were reviewed and
approved by an institutional review board (Quorum Re-
view) at each study center, and every patient provided writ-
ten informed consent.
Patient inclusion criteria
Men and women aged 18–65 years with relapsing forms
of MS, as defined by the 2005 revised McDonald criteria
[14], and an Expanded Disability Status Scale (EDSS)
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Patients were required to have received a single iDMT
(except natalizumab) continuously for at least 6 months
prior to study initiation and to be candidates for therapy
change. For patients from the USA, the treating physician
determined whether the patient was a suitable candidate
for therapy change. In the case of Canadian patients, only
those with relapsing–remitting MS and who had an inad-
equate response to, or were unable to tolerate, one or
more therapies for MS were eligible. Patients were re-
quired to have been naïve to fingolimod treatment.Patient exclusion criteria
Patients were excluded from the study for any of the fol-
lowing reasons: chronic immune system disease other
than MS; immunodeficiency; malignancy other than lo-
calized basal cell carcinoma within the past 5 years; a
history of cardiac arrest, myocardial infarction, ischemic
heart disease or coronary spasm within the past 6 months;
Mobitz type II second-degree heart block, third-degree
atrioventricular block or an increased corrected QT (QTc)
interval (>470 ms); having undergone a bone marrow
transplant; a history of alcohol abuse within the past
5 years. Further exclusion criteria at the time of screening
were: macular edema; active systemic infection; a negative
test for Varicella zoster immunoglobulin G antibodies;
positive tests for hepatitis B, hepatitis C or human im-
munodeficiency virus; tuberculosis; uncontrolled diabetes;
uncontrolled or poorly controlled hypertension or asthma;
cardiac failure; severe respiratory disease or pulmonary
fibrosis; chronic liver or biliary disease. Patients were
also excluded if they had been treated with the following
medications: immunosuppressants, immunoglobulins or
monoclonal antibodies within the 6 months before screen-
ing; any live or live attenuated vaccines during the month
before screening; cladribine, cyclophosphamide or mitox-
antrone at any time; class Ia or class III antiarrhythmic
drugs at the time of screening.Endpoints
For the primary and secondary post hoc study endpoints,
individual comparisons were conducted for all outcome
measures for switching to fingolimod compared with
remaining on any of the four individual iDMTs.Primary endpoint
The primary post hoc study endpoint was the least-squares
mean (LSM) change in Treatment Satisfaction Question-
naire for Medication (TSQM) Global Satisfaction score
from baseline to 6 months [15]. This was measured using
the Global Satisfaction subscale score on the TSQM v1.4,
where higher scores indicate greater satisfaction.Secondary endpoints
LSM changes from baseline to 6 months were calculated
for the TSQM Effectiveness, Side Effects and Convenience
subscale scores, again using TSQM v1.4. In the event that
more than one item was missing from a subscale score of
the TSQM, the subscale was considered invalid.
The 10-item Fatigue Severity Scale (FSS) was used to
assess fatigue severity and its effects on daily living, with
higher scores indicating greater fatigue severity [16]. The
Beck Depression Inventory-II (BDI-II), which contains
21 multiple-choice questions, was used to evaluate changes
in patient-reported depression during the trial; higher
scores indicate greater severity of depression [17]. The
Patient-Reported Outcome Indices for Multiple Sclerosis
(PRIMUS) Activities, a 15-item assessment [18], was used
to evaluate changes in activities of daily living, with higher
scores indicating greater activity limitation. For all of these
instruments, the result was specified as ‘missing’ if more
than 20% of the total number of scores were absent.
Health-related QOL was evaluated using the 36-item
Short-Form Health Survey (SF-36) v2, which is a self-
administered questionnaire measuring eight domains of
health [19]. These include physical functioning, role limi-
tations due to physical health, bodily pain, general health
perceptions, vitality, social functioning, role limitations
due to emotional problems and general mental health.
Higher scores indicate a better QOL. The SF-36 allows
the calculation of two summary scale scores: the Mental
Component Summary (MCS) and the Physical Compo-
nent Summary (PCS). For any of the eight domains, if
more than half of the questions were not answered, the
score for that domain was stated as ‘missing’; furthermore,
the MCS and PCS were also stated as ‘missing’ if any of
the eight scale scores were absent.
A further secondary endpoint, the physician-rated Clin-
ical Global Impressions of Improvement (CGI-I), provided
a global evaluation of clinical change over 6 months.
Using this scale, the physician scores a patient’s level of
improvement between 1 (very much improved since the
initiation of treatment) and 7 (very much worse since the
initiation of treatment) [20].
Statistical analyses
For the primary endpoint, enrollment of 1000 patients
(750 fingolimod; 250 iDMT) would provide 90% power
to detect a significant difference between fingolimod and
each iDMT group in the change from baseline, assuming
an effect size of 0.25, a significance level of 5% and a
10% rate of unevaluable patients.
Post hoc analyses were conducted using SAS software
v9.2 (SAS, Cary, NC, USA). For the analysis of individual
iDMTs, the primary variable was assessed using analysis
of covariance, with baseline TSQM Global Satisfaction
score as a covariate and treatment group as a main
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[13]. The differences in LSM change from baseline to
6 months between the treatment groups are reported,
with the exception of CGI-I where the differences be-
tween the mean scores after 6 months of treatment are




Study enrollment was completed in October 2011. Of
1053 patients randomized to treatment, 790 were ran-
domized to fingolimod 0.5 mg and 263 were randomized
to an iDMT. Of the patients switched to fingolimod, 262
switched from GA, 205 switched from IM IFN beta-1a,
196 switched from SC IFN beta-1a and 125 switched from
IFN beta-1b. For patients who remained on an iDMT, 74
remained on GA, 48 remained on IM IFN beta-1a, 58
remained on SC IFN beta-1a and 39 remained on IFN
beta-1b. Patients who switched from one iDMT to an-
other or who had been taking a therapy other than one of
the four study iDMTs prior to randomization were not in-
cluded in the analysis.
The eight study arms had similar baseline demographic
and disease characteristics (Table 1). The majority of
patients in each group were women (69.9–84.6%) and
Caucasian (75.0–86.5%), and the mean age ranged from
44.4 to 47.5 years (absolute range 18–65 years). In the year









(n = 262) (n = 74) (n = 205) (n = 4
Mean age (SD), years 46.3 (9.14) 44.4 (9.97) 46.6 (9.90) 45.1 (
Women, n (%) 208 (79.4) 61 (82.4) 160 (78.0) 38 (79
Race, n (%)
Caucasian 222 (84.7) 64 (86.5) 165 (80.5) 36 (75
Black 24 (9.2) 9 (12.2) 35 (17.1) 10 (20
Asian 2 (0.8) 0 (0.0) 0 (0.0) 0 (0.0
Native American 2 (0.8) 0 (0.0) 0 (0.0) 1 (2.1




13.1 (8.91) 12.2 (9.36) 12.0 (7.9) 11.5 (
Mean number of
MS relapses (SD)
Previous year 0.75 (5.53) 0.84 (3.12) 0.74 (5.54) 0.48 (
Previous 2 years 1.42 (9.60) 1.43 (5.81) 1.20 (7.78) 0.88 (
Mean EDSS
score (SD)
2.5 (1.33) 2.4 (1.35) 2.5 (1.26) 2.4 (1
EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; IFN, interferon; IM, inbetween 0.48 and 0.88 across all arms. The mean duration
of MS symptoms was 11.1–13.1 years from the point of
first symptom appearance and the mean EDSS score was
2.3–2.5 across all groups.
Primary endpoint by treatment
LSM changes (± standard error) in TSQM Global Satisfac-
tion scores from baseline to 6 months were significantly
superior following a switch to fingolimod compared with
remaining on GA (17.08 ± 1.56 versus 0.81 ± 2.89, respect-
ively), IM IFN beta-1a (17.57 ± 1.51 versus 2.10 ± 3.22, re-
spectively), SC IFN beta-1a (24.70 ± 1.62 versus 2.29 ±
2.96, respectively) or IFN beta-1b (22.34 ± 1.85 versus
4.45 ± 3.29, respectively); all p <0.001. Results are shown
in Figure 1.
Secondary endpoints by treatment
Treatment satisfaction questionnaire for medication
Effectiveness, Side Effects and Convenience subscales
LSM changes in scores for TSQM Effectiveness (12.16 ±
1.49 for fingolimod versus 0.62 ± 2.76 for GA; 13.31 ±
1.48 for fingolimod versus 1.37 ± 3.13 for IM IFN beta-
1a; 15.07 ± 1.65 for fingolimod versus 1.62 ± 3.02 for SC
IFN beta-1a; 17.59 ± 2.06 for fingolimod versus 0.68 ±
3.62 for IFN beta-1b), Side Effects (30.62 ± 1.56 for fin-
golimod versus 6.56 ± 3.27 for IM IFN beta-1a; 27.83 ±
1.43 for fingolimod versus −0.42 ± 2.61 for SC IFN beta-
1a; 21.50 ± 1.88 for fingolimod versus −1.24 ± 3.30 for IFN












8) (n = 196) (n = 58) (n = 125) (n = 39)
10.48) 45.0 (10.39) 45.9 (10.25) 46.3 (10.20) 47.5 (8.97)
.2) 137 (69.9) 44 (75.9) 94 (75.2) 33 (84.6)
.0) 160 (81.6) 44 (75.9) 94 (75.2) 31 (79.5)
.8) 29 (14.8) 14 (24.1) 24 (19.2) 6 (15.4)
) 0 (0.0) 0 (0.0) 1 (0.8) 0 (0.0)
) 2 (1.0) 0 (0.0) 0 (0.0) 0 (0.0)
) 5 (2.6) 0 (0.0) 6 (4.8) 2 (5.1)
7.87) 11.1 (7.89) 11.4 (8.04) 12.2 (8.64) 12.3 (6.78)
1.66) 0.76 (6.30) 0.88 (3.64) 0.74 (3.90) 0.62 (1.84)
2.72) 1.29 (8.54) 1.45 (5.05) 1.34 (5.50) 1.05 (2.83)
.27) 2.4 (1.35) 2.3 (1.38) 2.4 (1.37) 2.5 (1.39)












































Figure 1 Change in Treatment Satisfaction Questionnaire for Medication Global Satisfaction scores. The figure shows the LSM change
from baseline to 6 months ± standard error. GA, glatiramer acetate; IFN, interferon; iDMT, injectable disease-modifying therapy; IM, intramuscular;
LSM, least-squares mean; SC, subcutaneous.
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sus 5.70 ± 1.97 for IM IFN beta-1a; 42.36 ± 1.02 for fingoli-
mod versus 1.66 ± 1.87 for SC IFN beta-1a; 41.57 ± 1.15
for fingolimod versus 1.31 ± 2.04 for IFN beta-1b) were
superior at 6 months following a switch to fingolimod
compared with remaining on any of the four iDMTs (all
p <0.001), with the exception of TSQM Side Effects score
for fingolimod versus GA (9.25 ± 1.41 versus 4.47 ± 2.64,
respectively; p = 0.111). Results are shown in Table 2.
Beck depression inventory-II
LSM changes in BDI-II scores from baseline to 6 months
were significantly superior following a switch to fingoli-
mod compared with remaining on GA (−3.17 ± 0.46 ver-
sus −1.03 ± 0.86, respectively; p = 0.030), SC IFN beta-1a
(−2.73 ± 0.47 versus −0.10 ± 0.86, respectively; p = 0.007)
or IFN beta-1b (−4.16 ± 0.52 versus 0.14 ± 0.93, respect-
ively; p <0.001). No significant differences in LSM changes
were observed between switching to fingolimod and
remaining on IM IFN beta-1a (−3.21 ± 0.44 versus −2.26 ±
0.93, respectively; p = 0.358). Results are shown in Figure 2.
Fatigue severity scale
LSM changes in FSS scores from baseline to 6 months









(n = 262) (n = 74) (n = 205) (n = 48)
Effectiveness 12.16 ± 1.49 0.62 ± 2.76 13.31 ± 1.48 1.37 ± 3.13
Side effects 9.25 ± 1.41 4.47 ± 2.64 30.62 ± 1.56 6.56 ± 3.27
Convenience 38.01 ± 0.80 3.11 ± 1.49 43.83 ± 0.94 5.70 ± 1.97
Values are displayed as least-squares means ± standard errors. p <0.001 for all comp
GA, glatiramer acetate; IFN, interferon; IM, intramuscular; SC, subcutaneous; TSQM, Tcompared with remaining on SC IFN beta-1a (−0.44 ± 0.08
versus 0.15 ± 0.15, respectively; p <0.001) and IFN beta-1b
(−0.46 ± 0.09 versus 0.08 ± 0.16, respectively; p = 0.005). No
significant differences in LSM changes were observed
between switching to fingolimod and remaining on GA
(−0.18 ± 0.08 versus 0.03 ± 0.15, respectively; p = 0.218)
or IM IFN beta-1a (−0.33 ± 0.08 versus −0.07 ± 0.17, re-
spectively; p = 0.179). Results are shown in Figure 3.
Patient-reported outcome indices for multiple sclerosis
activities
LSM changes in PRIMUS Activities scores from baseline
to 6 months were not significantly different between
patients switched to fingolimod compared with those
remaining on GA (−0.25 ± 0.31 versus −0.40 ± 0.57, re-
spectively; p = 0.818), IM IFN beta-1a (−0.51 ± 0.28 ver-
sus −0.90 ± 0.59, respectively; p = 0.554), SC IFN beta-1a
(−0.77 ± 0.29 versus 0.06 ± 0.54, respectively; p = 0.182)
or IFN beta-1b (−0.93 ± 0.30 versus 0.03 ± 0.52, respect-
ively, p = 0.111).
36-item short-form health survey
Mental component summary LSM changes in SF-36
MCS scores from baseline to 6 months were significantly











(n = 196) (n = 58) (n = 125) (n = 39)
15.07 ± 1.65 1.62 ± 3.02 17.59 ± 2.06 0.68 ± 3.62
27.83 ± 1.43 −0.42 ± 2.61 21.50 ± 1.88 −1.24 ± 3.30
42.36 ± 1.02 1.66 ± 1.87 41.57 ± 1.15 1.31 ± 2.04
arisons; italics = non-significant result.










































Figure 2 Change in Beck Depression Inventory-II scores. The figure shows the LSM change from baseline to 6 months ± standard error. GA,
glatiramer acetate; iDMT, injectable disease-modifying therapy; IFN, interferon; IM, intramuscular; LSM, least-squares mean; SC, subcutaneous.
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1.39, respectively, p = 0.030). No significant differences in
LSM changes were observed between switching to fingoli-
mod and remaining on GA (2.27 ± 0.59 versus 0.13 ± 1.11,
respectively; p = 0.089), IM IFN beta-1a (2.38 ± 0.67 versus
1.81 ± 1.41, respectively; p = 0.719) or SC IFN beta-1a
(1.50 ± 0.63 versus 0.18 ± 1.14, respectively; p = 0.315). Re-
sults are shown in Figure 4.
Physical component summary LSM changes in SF-36
PCS scores from baseline to 6 months were significantly
superior following a switch to fingolimod compared with
remaining on SC IFN beta-1a (2.28 ± 0.47 versus 0.07 ±
0.85, respectively; p = 0.024) or IFN beta-1b (2.51 ± 0.65
versus −0.63 ± 1.19, respectively, p = 0.022). No signifi-
cant differences in LSM changes were observed between



































Figure 3 Change in Fatigue Severity Scale scores. The figure shows the
glatiramer acetate; iDMT, injectable disease-modifying therapy; IFN, interfer0.46 versus 0.65 ± 0.87, respectively; p = 0.606) or IM
IFN beta-1a (1.27 ± 0.48 versus 0.33 ± 1.01, respectively;
p = 0.400). Results are shown in Figure 5.
Clinical global impressions of improvement
Physicians perceived significantly greater clinical improve-
ment following a switch to fingolimod compared with
remaining on GA (CGI-I score at 6 months, 3.23 ± 0.07
versus 3.78 ± 0.13, respectively), IM IFN beta-1a (3.25 ±
0.08 versus 4.06 ± 0.16, respectively), SC IFN beta-1a
(3.11 ± 0.07 versus 3.98 ± 0.13, respectively) or IFN beta-1b
(3.35 ± 0.09 versus 3.97 ± 0.15, respectively); all p <0.001.
Results are shown in Figure 6.
Discussion
These post hoc analyses provide the first evidence of a












LSM change from baseline to 6 months ± standard error. GA,








































Figure 4 Change in 36-item Short-Form Health Survey Mental Component Summary scores. The figure shows the LSM change from
baseline to 6 months ± standard error. GA, glatiramer acetate; iDMT, injectable disease-modifying therapy; IFN, interferon; IM, intramuscular; LSM,
least-squares mean; SC, subcutaneous.
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iDMT, using a broad spectrum of patient satisfaction
and QOL measures, and methodology that is reflective
of the real-world use of fingolimod. Perceived improve-
ments in effectiveness and convenience, along with impact
on fatigue, depression and mental and physical wellbeing,
balanced against perceived tolerability and side effects
were evaluated as likely determinants of treatment satis-
faction in this study.
The main findings from the post hoc analyses support
the results of the primary EPOC study, namely that a
switch from GA or IFN beta to fingolimod is associated
with significantly better scores for the primary endpoint
of overall satisfaction with treatment. Here, benefits
from a switch of therapy to fingolimod were apparent
relative to each of the four iDMTs evaluated, rather than






























Figure 5 Change in 36-item Short-Form Health Survey Physical Comp
baseline to 6 months ± standard error. GA, glatiramer acetate; iDMT, injecta
least-squares mean; SC, subcutaneous.or a subset of therapies. The largest change in TSQM
Global Satisfaction score was observed as a result of a
switch to fingolimod from SC IFN beta-1a.
Patients also reported greater satisfaction following a
switch to fingolimod versus remaining on iDMTs in terms
of effectiveness, side effects and convenience. TSQM Ef-
fectiveness scores were superior for fingolimod compared
with all four iDMTs, with the largest change in score seen
following a switch from IFN beta-1b. TSQM Side Effects
scores were significantly improved following a switch to
fingolimod compared with remaining on each of the
iDMTs, except for GA. These findings are in line with
previous research showing that fingolimod is an effective
and generally well-tolerated therapy [9,10,21]. Change in
TSQM Convenience scores was significantly greater for
fingolimod versus all four iDMTs, with the greatest im-












onent Summary scores. The figure shows the LSM change from


































p < 0.001 p < 0.001 p < 0.001
Figure 6 Clinical Global Impressions of Improvement scores. The figure shows the mean score for clinician impressions of overall improvement
after 6 months of treatment. CGI-I, Clinical Global Impressions of Improvement; GA, glatiramer acetate; iDMT, injectable disease-modifying therapy; IFN,
interferon; IM, intramuscular; SC, subcutaneous.
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Again, this result is consistent with earlier research
showing a higher degree of patient satisfaction and
QOL associated with oral versus injectable therapies, as
well as adherence issues relating to repeated use of in-
jectable therapies [22-25].
Fatigue outcomes were significantly improved in pa-
tients who underwent a switch to fingolimod from SC
IFN beta-1a and IFN beta-1b. Fatigue is an extremely
common problem for patients with MS, with substantial
numbers reporting it to be a moderate-to-severe prob-
lem [26-29]. The variable effects on FSS scores shown
here are interesting, with superior scores reported for a
switch to fingolimod compared with remaining on either
of the SC IFN beta therapies, but not for a switch from
GA or IM IFN beta-1a. This suggests that individual
DMTs impact fatigue differently; this may be due to
varying effects on the components of fatigue (e.g. mental
versus physical). Alternatively, other factors such as vari-
ation in therapy adherence resulting from more or less
favorable dosing schedules may explain the pattern of
these results [30].
Depressive symptoms significantly improved following
a switch to fingolimod compared with remaining on
each of the iDMTs, except for IM IFN beta-1a. Several
authors report links between depression and fatigue
[31-34], with some finding particularly strong associa-
tions between depression and the mental component of
fatigue [34]. The prevalence of depression is high in pa-
tients with MS, and the frequency of major depression
exceeds that reported in individuals without MS and in
those with other illnesses [35]. Some studies in MS also
suggest that increasing disability is associated with wors-
ening BDI-II scores [36], although the root cause of de-
pression in MS is not known with certainty. Better control
of depression observed in patients switching to fingolimod(with the exception of the comparison with IM IFN beta-
1a, which also appeared to improve BDI-II scores in
contrast to findings of previous studies [36]) may there-
fore result from factors such as better control of disease
progression or reduction in fatigue, which may in turn
contribute to the improved satisfaction with treatment.
PRIMUS Activities scores showed no significant change
as a result of therapy switch to fingolimod from any of the
four iDMTs. This may suggest comparable levels of
impact of fingolimod and the four iDMTs on ability to
conduct daily activities, but it is also possible that the 6-
month duration of the EPOC study was not sufficiently
long to detect differences between fingolimod and each of
the iDMTs. This is an important consideration in light of
the significant improvement in the PRIMUS Activities
score reported in the 12-month TRANSFORMS phase 3
trial for fingolimod versus IM IFN beta-1a [9].
Changes in mental and physical functioning were sig-
nificantly greater as a result of switching from IFN beta-
1b to fingolimod, and change in PCS score was also
superior as a result of a switch to fingolimod from SC
IFN beta-1a. The changes in SF-36 MCS and PCS scores
as a result of switching to fingolimod support the concept
that fingolimod is capable of enhancing mental, emotional,
social and/or physical wellbeing in certain subsets of pa-
tients receiving iDMTs.
From the physician perspective, a switch to fingoli-
mod was associated with better CGI-I scores irrespect-
ive of prior iDMT. Overall, these results indicate that a
switch to fingolimod would significantly enhance im-
portant aspects of treatment satisfaction and QOL for
patients who are receiving these iDMTs. The physician-
reported CGI-I results are also reflective of the PROs;
this congruence between results is important, as the
CGI-I mirrors the content of the PROs used in this
study more closely than many traditional physician-
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biomedical factors (e.g. MRI outcomes) or are weighted
towards one particular factor (e.g. mobility in the case of
the EDSS score) that may not be fully reflective of how pa-
tients feel about the effect of MS on their lives. While
these traditional measures are undoubtedly important, a
scale such as the CGI-I helps to align physician assess-
ments with those of patient self-assessments, thus helping
to facilitate optimal treatment decisions.
One limitation of this study is that these data are un-
able to offer guidance on a switch in patients who are
satisfied with their particular iDMT treatment. It would
be of interest to determine whether fingolimod treatment
has a similarly significant impact on QOL in patients re-
ceiving iDMT, for whom MS is responsive to treatment,
and who are tolerant of their current therapy. A second
limitation is that the original study was not powered for
individual treatment group comparisons; however, most of
the comparisons were significant between treatment
groups, and provide the first evaluations in these regards
between fingolimod and active comparators (GA or IFN
beta) as opposed to placebo. With the effect size of 0.25
assumed in the protocol, the power to detect differences
in the TSQM Global Satisfaction score between fingoli-
mod and each of the active comparators given the sample
sizes seen in the study would range from 27% for IFN
beta-1b to 47% for GA. With the samples sizes seen for
the subgroups, and assuming 90% power, a range of effect
sizes from 0.43 to 0.61 could be detected in the TSQM
Global Satisfaction score. Thirdly, as the study utilized an
open-label design, lack of concealment had the potential
to increase estimates of treatment effects [37]; while the
open-label study design provides insight into the out-
comes that might be expected in real-world clinical
practice, and a control arm was included for objective
comparison, findings should be interpreted with caution
given the inherent potential for bias in any open-label
study. In particular, it should be noted that patients
were seeking a therapy switch. Despite this, a switch to
fingolimod significantly enhanced patient satisfaction and
outcomes scores across a wide range of measures. This
suggests that the beneficial effect of a switch is likely a fac-
tor of improved efficacy, tolerability and/or superior
disease-modifying properties of the therapy rather than
purely a result of the psychological impact of switching. It
is also possible that factors impacting QOL that are not
captured by the outcome measures used in this study may
have contributed to the improvements reported by both
patients and physicians. Finally, results should also be
interpreted with a degree of caution owing to the lack of
adjustment for multiplicity; however, in many instances,
particularly with TSQM and CGI-I, p values are less than
0.001, so these results would still be statistically significant
following any method of adjustment for multiplicity.For future studies, examination of the impact of chan-
ging to fingolimod from other DMTs on physician-
reported outcomes and PROs would also be of interest.
Analyses comparing the effect on relapse rates and MRI
outcomes for patients remaining on natalizumab versus a
switch to fingolimod in a similar patient population to the
EPOC study have recently been completed [38,39], but as
yet no data are available for PROs. To help address poten-
tial issues from lack of concealment, a study offering the
chance to switch from one class of iDMT to another (e.g.
GA to IFN beta) may be of interest (a small number of pa-
tients not included in these analyses underwent this switch,
but sample numbers were too small to conduct meaningful
analyses). This would increase confidence that the results
were driven by considerations other than simply remaining
on a therapy that was poorly tolerated or ineffectual. Sub-
group analyses may also be of value in identifying specific
patient groups who are eligible for therapy change and
who potentially stand to gain the most benefit from a
switch to fingolimod for the measures described in this
study. Subgroup analyses of the phase 3 FREEDOMS
study comparing fingolimod and placebo have identified
that most patients, from a patient population with a
broad range of clinical characteristics, showed reduced
relapse rates and disability progression when treated
with fingolimod [40]. These results provide a good ration-
ale for assessing treatment satisfaction and other PROs in
subgroups treated with fingolimod versus iDMTs.
Conclusions
It appears that patients with MS who are candidates for
a change in therapy from GA or IFN beta may demon-
strate significant improvements in a range of aspects of
QOL and PROs by switching to fingolimod therapy. This
could therefore have implications for patient preference
and physician decisions in the MS population described
in this study.
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